BPC-157: What 140 Preclinical Studies Actually Show

Compound Profile

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — 15 amino acids — derived via sequence truncation from a cytoprotective protein isolated from human gastric juice. The parent protein was identified in the 1990s by the research group of Sikiric et al. at the University of Zagreb, which has since produced the majority of the indexed preclinical literature.

As of 2026, PubMed indexes over 140 studies involving BPC-157. There are no published human randomised controlled trials. The compound remains unapproved by any major regulatory body.

Six Core Mechanisms

1. VEGFR2 Upregulation and Angiogenesis

The most consistently reported mechanism: BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2), driving angiogenesis — new capillary formation at injury sites. This is the mechanistic backbone of the tendon and wound healing literature. New vascular supply to avascular or hypovascular tissue (tendons, cartilage) accelerates the nutrient delivery required for repair.

2. FAK-Paxillin Pathway Activation

Focal adhesion kinase (FAK) and its binding partner paxillin govern cell migration, adhesion, and cytoskeletal organisation. BPC-157 activates this pathway, promoting the cell motility required for wound closure and tissue remodelling. This mechanism is relevant to both the dermal wound healing data and the musculoskeletal repair evidence.

3. Nitric Oxide System Upregulation

BPC-157 increases nitric oxide synthase (NOS) activity, elevating NO production. In the gastric mucosa, NO maintains mucosal blood flow, promotes mucus secretion, and supports epithelial tight junctions. This is the primary mechanism behind the gastric ulcer healing evidence — the most replicated finding in the entire BPC-157 literature, with multi-lab replication across ulcer models induced by NSAIDs, ethanol, and cysteamine.

4. NF-κB Pathway Suppression

BPC-157 downregulates nuclear factor kappa B (NF-κB) signalling — a master regulator of the inflammatory response. NF-κB suppression reduces production of TNF-α, IL-1β, and IL-6. This mechanism is cited in inflammatory bowel disease models, arthritis models, and systemic inflammation studies within the preclinical dataset.

5. Dopaminergic and Serotonergic Modulation

A less-studied but indexed finding: BPC-157 influences both dopaminergic and serotonergic transmission. In rodent models, it modulates dopamine synthesis and receptor sensitivity. This is the mechanism basis for the neuroprotection and neurological recovery data — including models of traumatic brain injury and Parkinson's-like dopamine depletion.

6. Growth Hormone Receptor Pathway Interaction

Several bone and muscle repair studies suggest BPC-157 interacts with growth hormone receptor (GHR) signalling, potentially sensitising downstream pathways. This mechanism is less well-characterised than the VEGFR2 or NO system data and carries a lower evidence grade.

Evidence by Body System

Grade A: replicated by multiple independent laboratories across multiple models. Grade B: replicated within or across a small number of groups, mechanistically plausible. Grade C: preliminary data, single-group or limited model scope.

The Human Data Problem

The complete absence of human RCT data is the central limitation of the BPC-157 evidence base. Every study cited is in rodents (primarily rats) or in vitro. The translational assumptions required to apply this data to human research are substantial.

Dose translation uses body surface area scaling. The standard rat-to-human equivalent dose (HED) conversion factor is ÷6.2 (FDA guidance). For the most commonly cited rat dose range of 10 µg/kg to 10 mg/kg:

• Lower end (10 µg/kg in rats): HED ≈ 1.6 µg/kg in humans → ~112 µg for a 70 kg subject
• Upper end: HED approaches milligram-scale dosing

Research reference doses commonly cited in the literature fall between 200–500 µg/day subcutaneous, though this is derived from HED extrapolation, not human pharmacokinetic data.

Stability and Formulation Notes

BPC-157 is relatively stable in acidic pH (consistent with its gastric origin) but degrades in alkaline conditions. Lyophilised storage at −20°C is stable for 12–24 months. Reconstituted in bacteriostatic water at 2–8°C, the window is approximately 28 days. Freeze-thaw cycling of reconstituted solution degrades peptide integrity and should be avoided.

GLP Protocol Context

BPC-157 is co-administered with GLP-1 agonists in research protocols for mechanistic reasons: GLP compounds slow gastric motility and trigger mucosal stress responses in 30–50% of subjects. BPC-157's NO-mediated gastroprotection and tight junction restoration map directly onto these effects. The co-administration is mechanistically rational regardless of the specific GLP compound used.

Referenced Compounds

Best Seller

99.3%

BPC-157 10mg

Body Protection Compound-157

15-amino-acid synthetic pentadecapeptide. 140+ preclinical studies; upregulates VEGFR2 and FAK-paxillin signalling for tissue repair. 99.3% purity. Standard research vial.

$59.99

CAS 137525-51-0

Order